# Lasa Supergenerics (NSE: LASA) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/LASA · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹37 Cr, it ranks 3259th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was −17.6% in FY25. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was −₹0 Cr (−100.3% year on year) and net profit −₹4 Cr, on a standalone basis. Promoters held 53.65% of the company as of 31 Mar 2026; 20.66% of promoter shares were pledged.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹37 Cr |
| ROE | −17.6% (FY25) |
| ROCE | −1.2% (FY25) |
| Debt to equity | 0 |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q4 FY26 | −₹0 Cr | −100.3% | −₹4 Cr | — | −₹0.83 |
| Q3 FY26 | ₹2 Cr | −93.3% | −₹3 Cr | −146.4% | −₹0.51 |
| Q2 FY26 | ₹3 Cr | −92.2% | −₹6 Cr | — | −₹1.25 |
| Q1 FY26 | ₹20 Cr | −35.1% | −₹21 Cr | — | −₹4.22 |
| Q4 FY25 | ₹39 Cr | +71.5% | −₹14 Cr | — | −₹2.85 |
| Q3 FY25 | ₹33 Cr | +24.1% | ₹5 Cr | — | ₹1.10 |
| Q2 FY25 | ₹39 Cr | +62.1% | −₹3 Cr | — | −₹0.64 |
| Q1 FY25 | ₹31 Cr | +0.9% | −₹3 Cr | — | −₹0.55 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹142 Cr | −₹15 Cr |
| FY24 | ₹104 Cr | −₹22 Cr |
| FY23 | ₹130 Cr | −₹39 Cr |
| FY22 | ₹137 Cr | −₹5 Cr |
| FY21 | ₹202 Cr | ₹23 Cr |
| FY20 | ₹167 Cr | ₹4 Cr |

## Shareholding (31 Mar 2026)

- Promoters: 53.65%
- Non-institutions: 46.35%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Sandu Pharma](https://app.pivotnow.in/stock/SANDUPHQ) | — | ₹41 Cr | — | — |
| [Medicamen Organ](https://app.pivotnow.in/stock/MEDIORG) | ₹25.45 | ₹38 Cr | 3.5 | — |
| [Roopa Ind](https://app.pivotnow.in/stock/ROOPAIND) | — | ₹38 Cr | — | — |
| [JFL Life Scienc](https://app.pivotnow.in/stock/JFLLIFE) | ₹10.30 | ₹34 Cr | 0.2 | — |
| [Chandra Bhagat](https://app.pivotnow.in/stock/CBPL) | — | ₹33 Cr | — | — |
| [Sharma East Ind](https://app.pivotnow.in/stock/SHARMEH) | — | ₹33 Cr | — | — |

## Questions and answers

### What is the market cap of Lasa Supergenerics?

Lasa Supergenerics' market capitalisation is ₹37 Cr (₹37 Cr) at the 22 Oct 2026 close, ranking 3259th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Lasa Supergenerics?

Return on equity was −17.6% in FY25 and return on capital employed was −1.2% in FY25 (standalone figures).

### Is Lasa Supergenerics a debt-free company?

Lasa Supergenerics is close to debt-free: its debt-to-equity ratio was 0 in FY25.

### What were Lasa Supergenerics' latest quarterly results?

For Q4 FY26 (quarter ended 31 Mar 2026), Lasa Supergenerics reported revenue of −₹0 Cr, −100.3% year on year, and net profit of −₹4 Cr.

### What is the shareholding pattern of Lasa Supergenerics?

As of 31 Mar 2026: promoters 53.65%, non-institutions 46.35%. 20.66% of promoter shares were pledged.

### Who are Lasa Supergenerics' competitors?

The listed Pharma & Healthcare companies closest to Lasa Supergenerics by market cap are Sandu Pharma, Medicamen Organ, Roopa Ind, JFL Life Scienc, Chandra Bhagat and Sharma East Ind.

### Is Lasa Supergenerics a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Lasa Supergenerics' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on LASA against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.